Literature DB >> 9776445

Clinical and pathophysiological significance of severe neurotrauma in polytraumatized patients.

J Meixensberger1, K Roosen.   

Abstract

INTRODUCTION: Traumatic brain injury (TBI) is present in up to two-thirds of multiply injured patients. The degree of TBI influenced the mortality and morbidity of multiple trauma significantly.
RESULTS: Important prognostic predictors are: injury severity score (ISS); Glasgow coma score [(GCS), motor score]; pupil size and reactivity; coma grade and duration; age; morphological primary brain lesion; and pathophysiological changes leading to secondary brain damage. The time course of brain edema, raised intracranial pressure and, especially, pathophysiology of disturbed cerebral blood flow and metabolism characterizes early and late periods of ischemic vulnerability.
CONCLUSION: These should be taken into consideration when planning operative procedures in multiple-trauma patients. Avoidance of secondary ischemic brain damage by reducing the number of systemic insults (hypovolemia, hypotension, hypoxia) will improve prognosis of critically ill polytraumatized patients with head injury.

Entities:  

Mesh:

Year:  1998        PMID: 9776445     DOI: 10.1007/s004230050121

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  3 in total

1.  [Diagnosis and treatment of traumatic brain injury].

Authors:  E Rickels
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

2.  Systemic inflammatory effects of traumatic brain injury, femur fracture, and shock: an experimental murine polytrauma model.

Authors:  C Probst; M J Mirzayan; P Mommsen; C Zeckey; T Tegeder; L Geerken; M Maegele; A Samii; M van Griensven
Journal:  Mediators Inflamm       Date:  2012-03-04       Impact factor: 4.711

3.  The role of markers of inflammation in traumatic brain injury.

Authors:  Thomas Woodcock; Maria Cristina Morganti-Kossmann
Journal:  Front Neurol       Date:  2013-03-04       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.